Nucleix Presents Clinical Data at EAU21 Virtual Congress Which Demonstrates Promising Advances in the Care of Bladder Cancer Patients
Share: Data Includes First Real World Evidence on Alternating Bladder EpiCheck® and Cystoscopy for Surveillance of Non-Muscle Invasive Bladder Cancer (NMIBC) Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced data from two abstracts featuring its Bladder EpiCheck® test at the 36th Annual European Association of Urology (EAU) Virtual Congress. The first abstract titled, "Real world evidence of alternating cystoscopy/cytology with Bladder EpiCheck in NMIBC surveillance," shows the results of a pilot performed at Radboud Universi...
Source: benzinga.com